Chymotrypsin-like proteases contribute to human monocytic THP-1 cell as well as human microglial neurotoxicity

GLIA

Volumn 51, Issue 1, 2005, Pages 56-64

  Klegeris, Andis ^a   Mcgeer, Patrick L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Alzheimer's disease; Enzyme inhibitors; Neuroblastoma; Neuroinflammation; SH SY5Y

Indexed keywords

3,4 DICHLOROISOCOUMARIN; 4 (2 AMINOETHYL)BENZENESULFONYL FLUORIDE; ALPHA 1 ANTICHYMOTRYPSIN; BROMOENOL LACTONE; CHYMOSTATIN; CHYMOTRYPSIN; PROTEINASE; GAMMA INTERFERON; HYDROGEN PEROXIDE; LACTATE DEHYDROGENASE; SERINE PROTEINASE INHIBITOR; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL LINE; CYTOTOXICITY; DRUG INHIBITION; HUMAN; HUMAN CELL; MICROGLIA; MONOCYTE; NEUROTOXICITY; PRIORITY JOURNAL; CELL CULTURE; CELL FRACTIONATION; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; DRUG EFFECT; METABOLISM; PATHOLOGY; PHYSIOLOGY; STIMULATION; TEMPORAL LOBE; TOXICITY AND INTOXICATION;

CELL LINE; CELL SURVIVAL; CELLS, CULTURED; CHYMOTRYPSIN; HUMANS; HYDROGEN PEROXIDE; INTERFERON TYPE II; L-LACTATE DEHYDROGENASE; MICROGLIA; MONOCYTES; NEUROTOXICITY SYNDROMES; SERINE PROTEINASE INHIBITORS; STIMULATION, CHEMICAL; SUBCELLULAR FRACTIONS; TEMPORAL LOBE; TETRAZOLIUM SALTS; THIAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 22444442864     PISSN: 08941491     EISSN: None     Source Type: Journal    
DOI: 10.1002/glia.20186     Document Type: Article

References (72)

1. Adams DO. 1980. Effector mechanisms of cytolytically activated macrophages. I. Secretion of neutral proteases and effect of protease inhibitors. J Immunol 124:286-292.
2. Bissonnette CJ, Klegeris A, McGeer PL, McGeer EG. 2004. Interleukin 1α and interleukin 6 protect neuronal SH-SY5Y cells from oxidative damage. Neurosci Lett 361:40-43.
3. Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A. 2003. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60:1059-1064.
4. Christie G, Markwell RE, Gray CW, Smith L, Godfrey F, Mansfield F, Wadsworth H, King R, McLaughlin M, Cooper DG, Ward RV, Howlett DR, Hartmann T, Lichtenthaler SF, Beyreuther K, Underwood J, Gribble SK, Cappai R, Masters CL, Tamaoka A, Gardner RL, Rivett AJ, Karran EH, Allsop D. 1999. Alzheimer's disease: correlation of the suppression of β-amyloid peptide secretion from cultured cells with inhibition of the chymotrypsin-like activity of the proteasome. J Neurochem 73:195-204.
5. Ciesielski-Treska J, Ulrich G, Chasserot-Golaz S, Zwiller J, Revel MO, Aunis D, Bader MF. 2001. Mechanisms underlying neuronal death induced by chromogranin A-activated microglia. J Biol Chem 276:13113-13120.
6. Colton CA, Chernyshev ON, Gilbert DL, Vitek MP. 2000. Microglial contribution to oxidative stress in Alzheimer's disease. Ann NY Acad Sci 899:292-307.
7. Combs CK, Johnson DE, Cannady SB, Lehman TM, Landreth GE. 2000. Inflammatory mechanisms in Alzheimer's disease: inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists. J Neurosci 20:558-567.
8. Combs CK, Karlo JC, Kao SC, Landreth GE. 2001. β-Amyloid stimulation of microglia and monocytes results in TNF α-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci 21:1179-1188.
9. De Groot CJA, Langeveld CH, Jongenelen CAM, Montagne L, Van Der Valk P, Dijkstra C. 1997. Establishment of human adult astrocyte cultures derived from postmortem multiple sclerosis and control brain and spinal cord regions: immunophenotypical and functional characterization. J Neurosci Res 49:342-354.
10. De Groot CJA, Montagne L, Janssen I, Ravid R, Van Der Valk P, Veerhuis R. 2000. Isolation and characterization of adult microglial cells and oligodendrocytes derived from postmortem human brain tissue. Brain Res Protocols 5:85-94.
11. Decker T, Lohmann-Matthes ML. 1988. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 15:61-69.
12. Denis M. 1994. Human monocytes/macrophages: NO or no NO? J Leukocyte Biol 55:682-684.
13. Dzenko KA, Weltzien RB, Pachter JS. 1997. Suppression of Aβ-induced monocyte neurotoxicity by antiinflammatory compounds. J Neuroimmunol 80:6-12.
14. Eikelenboom P, van Gool WA. 2004. Neuroinflammatory perspectives on the two faces of Alzheimer's disease. J Neural Transm 111:281-294.
15. Fiszer U. 2001. Does Parkinson's disease have an immunological basis? The evidence and its therapeutic implications. Biodrugs 15:351-355.
16. Flavin MP, Ho LT, Coughlin K. 1997. Neurotoxicity of soluble macrophage products in vitro-influence of dexamethasone. Exp Neurol 145:462-470.
17. Flavin MP, Zhao G, Ho LT. 2000. Microglial tissue plasminogen activator (tPA) triggers neuronal apoptosis in vitro. Glia 29:347-354.
18. Gan L, Ye S, Chu A, Anton K, Yi S, Vincent VA, von Schack D, Chin D, Murray J, Lohr S, Patthy L, Gonzalez-Zulueta M, Nikolich K, Urfer R. 2004. Identification of cathepsin B as a mediator of neuronal death induced by Aβ-activated microglial cells using a functional genomics approach. J Biol Chem 279:5565-5572.
19. Giulian D, Vaca K, Noonan CA. 1990. Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1. Science 250:1593-1596.
20. Gottschall PE. 1996. β-Amyloid induction of gelatinase B secretion in cultured microglia: inhibition by dexamethasone and indomethacin. NeuroReport 7:3077-3080.
21. Griscavage JM, Wilk S, Ignarro LJ. 1995. Serine and cysteine proteinase inhibitors prevent nitric oxide production by activated macrophages by interfering with transcription of the inducible NO synthase gene. Biochem Biophys Res Commun 215:721-729.
22. Hanisch UK. 2002. Microglia as a source and target of cytokines. Glia 40:140-155.
23. Hansen MB, Nielsen SE, Berg K. 1989. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119:203-210.
24. He BP, Wen W, Strong MJ. 2002. Activated microglia (BV-2) facilitation of TNF-α-mediated motor neuron death in vitro. J Neuroimmunol 128:31-38.
25. Heyes MP, Achim CL, Wiley CA, Major EO, Saito K, Markey SP. 1996. Human microglia convert L-tryptophan into the neurotoxin quinolinic acid. Biochem J 320:595-597.
26. In't Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MMB, Stricker BHC. 2001. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345:1515-1521.
27. Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, Coppola D, Morgan D, Gordon MN. 2002. Microglial activation and β-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 22:2246-2254.
28. Jourquin J, Tremblay E, Decanis N, Charton G, Hanessian S, Chollet AM, Le Diguardher T, Khrestchatisky M, Rivera S. 2003. Neuronal activity-dependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate. Eur J Neurosci 18:1507-1517.
29. Kantarci OH, Schaefer-Klein JL, Hebrink DD, Achenbach SJ, Atkinson EJ, McMurray CT, Weinshenker BG. 2003. A population-based study of IL-4 polymorphisms in multiple sclerosis. J Neuroimmunol 137:134-139.
30. Kingham PJ, Pocock JM. 2001. Microglial secreted cathepsin B induces neuronal apoptosis. J Neurochem 76:1475-1484.
31. Klegeris A, Walker DG, McGeer PL. 1999. Toxicity of human THP-1 monocytic cells towards neuron-like cells is reduced by non-steroidal anti-inflammatory drugs (NSAIDs). Neuropharmacology 38:1017-1025.
32. Klegeris A, Bissonnette CJ, McGeer PL. 2003. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid type CB2 receptor. Br J Pharmacol 139:775-786.
33. Klegeris A, Bissonnette CJ, McGeer PL. 2005. Modulation of human microglia and THP-1 cell toxicity by cytokines endogenous to the nervous system. Neurobiol Aging 26:673-682.
34. Lee YB, Nagai A, Kim SU. 2002. Cytokines, chemokines, and cytokine receptors in human microglia. J Neurosci Res 69:94-103.
35. Licastro F, Davis LJ, Morini MC, Cucinotta D, Savorani G. 1994. Cerebrospinal fluid of patients with senile dementia of Alzheimer's type shows an increased inhibition of α-chymotrypsin. Alzheimers Dis Assoc Dis 8:241-249.
36. Licastro F, Grimaldi LME, Bonafe M, Martina C, Olivieri F, Cavallone L, Giovagnetti S, Masliah E, Franceschi C. 2003. Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the cytokine in blood and brain. Neurobiol Aging 24:921-926.
37. Lim GP, Yang F, Chu T, Gahtan E, Ubeda O, Beech W, Overmier JB, Hsiao-Ashec K, Frautschy SA, Cole GM. 2001. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging 22:983-991.
38. Liu J, Zhao ML, Brosnan CF, Lee SC. 1996. Expression of type II nitric oxide synthase in primary human astrocytes and microglia: role of IL-1β and IL-1 receptor antagonist. J Immunol 157:3569-3576.
39. London JA, Biegel D, Pachter JS. 1996. Neurocytopathic effects of β-amyloid-stimulated monocytes: a potential mechanism for central nervous system damage in Alzheimer disease. Proc Natl Acad Sci USA 93:4147-4152.
40. McCawley LJ, Matrisian LM. 2001. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 13:534-540.
41. McGeer PL, McGeer EG. 1999. Inflammation of the brain in Alzheimer's disease: implications for therapy. J Leukocyte Biol 65:409-415.
42. McGeer PL, McGeer EG. 2001. Polymorphisms in inflammatory genes and the risk of Alzheimer disease. Arch Neurol 58:1790-1792.
43. McGeer PL, McGeer EG. 2002. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 26:459-470.
44. McGeer PL, Schulzer M, McGeer EG. 1996. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies. Neurology 47:425-432.
45. McGeer PL, Yasojima K, McGeer EG. 2002. Association of interleukin-1β polymorphisms with idiopathic Parkinson's disease. Neurosci Lett 326:67-69.
46. McMillian MK, Vainio PJ, Tuominen RK. 1997. Role of protein kinase C in microglia-induced neurotoxicity in mesencephalic cultures. J Neuropathol Exp Neurol 56:301-307.
47. Moriguchi S, Mizoguchi Y, Tomimatsu Y, Hayashi Y, Kadowaki T, Kagamiishi Y, Katsube N, Yamamoto K, Inoue K, Watanabe S, Nabekura J, Nakanishi H. 2003. Potentiation of NMDA receptor-mediated synaptic responses by microglia. Brain Res Mol Brain Res 119:160-169.
48. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
49. Nakajima K, Kohsaka S. 2004. Microglia: neuroprotective and neurotrophic cells in the central nervous system. Curr Drug Targets Cardiovasc Haematol Dis 4:65-84.
50. Nakanishi H. 2003. Microglial functions and proteases. Mol Neurobiol 27:163-176.
51. Navikas V, Link H. 1996. Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res 45:322-333.
52. Neuroinflammation Working Group. 2000. Inflammation and Alzheimer's disease. Neurobiol Aging 21:383-421.
53. Perona JJ, Craik CS. 1997. Evolutionary divergence of substrate specificity within the chymotrypsin-like serine protease fold. J Biol Chem 272:29987-29990.
54. Peterson PK, Hu S, Anderson WR, Chao CC. 1994. Nitric oxide production and neurotoxicity mediated by activated microglia from human versus mouse brain. J Infect Dis 170:457-460.
55. Piani D, Spranger M, Frei K, Schaffner A, Fontana A. 1992. Macrophage-induced cytotoxicity of N-methyl-D-aspartate receptor positive neurons involves excitatory amino acids rather than reactive oxygen intermediates and cytokines. Eur J Immunol 22:2429-2436.
56. Puente XS, Sanchez LM, Overall CM, Lopez-Otin C. 2003. Human and mouse proteases: a comparative genomic approach. Nature Rev Genet 4:544-558.
57. Schulte T, Schols L, Muller T, Woitalla D, Berger K, Kruger R. 2002. Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson's disease. Neurosci Lett 326:70-72.
58. Schwab C, Hosokawa M, McGeer PL. 2004. Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. Exp Neurol 188:52-64.
59. Siao CJ, Fernandez SR, Tsirka SE. 2003. Cell type-specific roles for tissue plasminogen activator released by neurons or microglia after excitotoxic injury. J Neurosci 23:3234-3242.
60. Stewart WF, Kawas C, Corrada M, Metter EJ. 1997. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48:626-632.
61. Streit WJ. 1993. Microglial-neuronal interactions. J Chem Neuroanat 6:261-266.
62. Tanaka M, Sotomatsu A, Yoshida T, Hirai S, Nishida A. 1994. Detection of superoxide production by activated microglia using sensitive and specific chemiluminescence assay and microglia-mediated PC12h cell death. J Neurochem 63:266-270.
63. Taylor DL, Diemel LT, Pocock JM. 2003. Activation of microglial group III metabotropic glutamate receptors protects neurons against microglial neurotoxicity. J Neurosci 23:2150-2160.
64. Uryu S, Tokuhiro S, Murasugi T, Oda T. 2002. A novel compound, RS-1178, specifically inhibits neuronal cell death mediated by β-amyloid-induced macrophage activation in vitro. Brain Res 946:298-306.
65. Vandenbroeck K, Martine G, Marrosu M, Consiglio A, Zaffaroni M, Vaccargiu S, Franciotta D, Ruggeri M, Comi G, Grimaldi LM. 1997. Occurrence and clinical relevance of an interleukin-4 gene polymorphism in patients with multiple sclerosis. J Neuroimmunol 76:189-192.
66. Walker DG, Lue L-F, Beach TG. 2001. Gene expression profiling of amyloid beta peptide-stimulated human post-mortem brain microglia. Neurobiol Aging 22:957-966.
67. 1-42- and lipopolysaccharide-activated microglia. J Neurosci 22:3484-3492.
68. Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL, Citron M, Landreth G. 2003. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23:7504-7509.
69. Yeh MW, Kaul M, Zheng J, Nottet HS, Thylin M, Gendelman HE, Lipton SA. 2000. Cytokine-stimulated, but not HIV-infected, human monocyte-derived macrophages produce neurotoxic levels of L-cysteine. J Immunol 164:4265-4270.
70. Zhan SS, Veerhuis R, Kamphorst W, Eikelenboom P. 1995. Distribution of beta amyloid associated proteins in plaques in Alzheimer's disease and in the non-demented elderly. Neurodegeneration 4:291-297
71. Zhang K, McQuibban GA, Silva C, Butler GS, Johnston JB, Holden J, Clark-Lewis I, Overall CM, Power C. 2003. HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nature Neurosci 6:1064-1071.
72. 1-antichymotrypsin and the correlation with Alzheimer's disease. Alzheimers Dis 4:115-122.